Poziotinib’s Shift Of Focus To HER2 May Increase Approval Chances

Potential First-Line Therapy

Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.

positive
No Specific Approved NSCLS Therapy So Far For HER2 Exon 20 Insertion Mutation • Source: Alamy

Spectrum Pharmaceuticals Inc. presented positive data from Cohort 4 of the Phase II ZENITH20 study with poziotinib in the first-line setting in non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations at the recent European Society for Medical Oncology (ESMO) Congress, showing the drug's potential in an area with high unmet need and few available treatment options.

Poziotinib, licensed in from South Korea’s Hanmi Pharmaceutical Co., Ltd., is an oral, irreversible, tyrosine kinase inhibitor being investigated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By 

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

More from R&D

Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win

 

The biotech announced positive results in the PIK3CA wild-type population in second-line HR+/HER2- breast cancer for its PAM inhibitor.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

Bayer’s Elinzanetant Is Latest Drug Hit By FDA Review Delays

 
• By 

Comes Days After PDUFA Pushback For GSK's Blenrep.